Next, we aimed to ascertain whether tumor cells overexpressing GLS2 constitutively (T98G-GAB) or after induction of differentiation by PMA treatment (SH-SY5Y) shift their cellular populations toward cell cycle stages compatible with lower proliferation. The gene discussed is GLS2; the disease is neoplasm.